A Single-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of Inclisiran in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (ORION-7)
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2018
At a glance
- Drugs Inclisiran (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Acronyms ORION-7
- Sponsors The Medicines Company
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 19 Feb 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.